The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6

Cancer Letters

Volumn 359, Issue 2, 2015, Pages 250-258

  Lu, Kang ^a   Fang, Xiao Sheng ^a   Feng, Li Li ^a   Jiang, Yu Jie ^a   Zhou, Xiang Xiang ^a   Liu, Xin ^a   Li, Pei Pei ^a   Chen, Na ^a   Ding, Mei ^a   Wang, Na ^a   Zhang, Jie ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Histone deacetylase; Interleukin 6; STAT3

Indexed keywords

3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; PANOBINOSTAT; PROTEIN BCL XL; PROTEIN MCL 1; RECOMBINANT INTERLEUKIN 6; STAT3 PROTEIN; VORINOSTAT; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; HYDROXAMIC ACID; IL6 PROTEIN, HUMAN; INDOLE DERIVATIVE; MCL1 PROTEIN, HUMAN; MYELOID LEUKEMIA FACTOR 1; PROTEIN BCL X; PYRIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN; TYRPHOSTIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW STROMA CELL; CANCER RESISTANCE; CELL PROTECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; STROMA CELL; TUMOR CELL CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; CELL SURVIVAL; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; INTERLEUKIN-6; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIDINES; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 84923081350     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.021     Document Type: Article

References (60)

1. Rozovski U., Hazan-Halevy I., Keating M.J., Estrov Z. Personalized medicine in CLL: current status and future perspectives. Cancer Lett 2014, 352:4-14.
2. Dighiero G., Hamblin T.J. Chronic lymphocytic leukaemia. Lancet 2008, 371:1017-1029.
3. Foa R. Changes in the treatment landscape for chronic lymphoid leukemia. N. Engl. J. Med 2014, 371:273-274.
4. Lu K., Wang X. Therapeutic advancement of chronic lymphocytic leukemia. J. Hematol. Oncol 2012, 5:55.
5. Burger J.A., Gribben J.G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin. Cancer Biol 2014, 24:71-81.
6. Gilbert L.A., Hemann M.T. Chemotherapeutic resistance: surviving stressful situations. Cancer Res 2011, 71:5062-5066.
7. Audrito V., Vaisitti T., Serra S., Bologna C., Brusa D., Malavasi F., et al. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Lett 2013, 328:27-35.
8. Schulz A., Toedt G., Zenz T., Stilgenbauer S., Lichter P., Seiffert M. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica 2011, 96:408-416.
9. Ten Hacken E., Burger J.A. Microenvironment dependency in Chronic Lymphocytic Leukemia: the basis for new targeted therapies. Pharmacol. Ther 2014, 144:338-348.
10. Fayad L., Keating M.J., Reuben J.M., O'Brien S., Lee B.N., Lerner S., et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001, 97:256-263.
11. Sun X., Mao Y., Wang J., Zu L., Hao M., Cheng G., et al. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene 2014, 33:4450.
12. Plander M., Ugocsai P., Seegers S., Orso E., Reichle A., Schmitz G., et al. Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma. Ann. Hematol 2011, 90:1381-1390.
13. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527.
14. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
15. Hu Y., Chen H., Duan C., Liu D., Qian L., Yang Z., et al. Deficiency of Erbin induces resistance of cervical cancer cells to anoikis in a STAT3-dependent manner. Oncogenesis 2013, 2:e52.
16. Yoon J.Y., Lafarge S., Dawe D., Lakhi S., Kumar R., Morales C., et al. Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 2012, 53:1735-1742.
17. Lai R., O'Brien S., Maushouri T., Rogers A., Kantarjian H., Keating M., et al. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 2002, 95:1071-1075.
18. Van Damme M., Crompot E., Meuleman N., Mineur P., Bron D., Lagneaux L., et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 2012, 7:1403-1412.
19. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009, 280:168-176.
20. Rius M., Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene 2012, 31:4257-4265.
21. Tan J., Cang S., Ma Y., Petrillo R.L., Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol 2010, 3:5.
22. Stamatopoulos B., Meuleman N., De Bruyn C., Delforge A., Bron D., Lagneaux L. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010, 95:1136-1143.
23. Bodo J., Zhao X., Sharma A., Hill B.T., Portell C.A., Lannutti B.J., et al. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Br. J. Haematol 2013, 163:72-80.
24. Ralli R., Banks K.M., Wiegmans A.P., Carney D., Seymour J.F., Johnstone R.W., et al. Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro. Leukemia 2012, 26:1433-1435.
25. DeAngelo D.J., Spencer A., Bhalla K.N., Prince H.M., Fischer T., Kindler T., et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013, 27:1628-1636.
26. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
27. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
28. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
29. Vianello F., Villanova F., Tisato V., Lymperi S., Ho K.K., Gomes A.R., et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica 2010, 95:1081-1089.
30. Galluzzi L., Aaronson S.A., Abrams J., Alnemri E.S., Andrews D.W., Baehrecke E.H., et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009, 16:1093-1107.
31. Steele A.J., Prentice A.G., Cwynarski K., Hoffbrand A.V., Hart S.M., Lowdell M.W., et al. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 2010, 116:4569-4577.
32. Yuan Z.L., Guan Y.J., Chatterjee D., Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307:269-273.
33. Steele A.J., Prentice A.G., Hoffbrand A.V., Yogashangary B.C., Hart S.M., Lowdell M.W., et al. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood 2009, 114:1217-1225.
34. Kurtova A.V., Balakrishnan K., Chen R., Ding W., Schnabl S., Quiroga M.P., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009, 114:4441-4450.
35. Rosich L., Saborit-Villarroya I., Lopez-Guerra M., Xargay-Torrent S., Montraveta A., Aymerich M., et al. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica 2013, 98:1739-1747.
36. Sampath D., Liu C., Vasan K., Sulda M., Puduvalli V.K., Wierda W.G., et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012, 119:1162-1172.
37. Buggins A.G., Patten P.E., Richards J., Thomas N.S., Mufti G.J., Devereux S. Tumor-derived IL-6 may contribute to the immunological defect in CLL. Leukemia 2008, 22:1084-1087.
38. Emilie D., Leger-Ravet M.B., Devergne O., Raphael M., Peuchmaur M., Coumbaras J., et al. Intratumoral production of IL-6 in B cell chronic lymphocytic leukemia and B lymphomas. Leukemia & Lymphoma 1993, 11:411-417.
39. Moreno A., Villar M.L., Camara C., Luque R., Cespon C., Gonzalez-Porque P., et al. Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood 2001, 97:242-249.
40. Yang J., Wezeman M., Zhang X., Lin P., Wang M., Qian J., et al. reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 2007, 12:252-265.
41. Schneider B.J., Kalemkerian G.P., Bradley D., Smith D.C., Egorin M.J., Daignault S., et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest. New Drugs 2012, 30:249-257.
42. Ramalingam S.S., Kummar S., Sarantopoulos J., Shibata S., LoRusso P., Yerk M., et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J. Clin. Oncol 2010, 28:4507-4512.
43. Sharma S., Witteveen P.O., Lolkema M.P., Hess D., Gelderblom H., Hussain S.A., et al. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother. Pharmacol 2015, 75:87-95.
44. Shapiro G.I., Frank R., Dandamudi U.B., Hengelage T., Zhao L., Gazi L., et al. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother. Pharmacol 2012, 69:555-562.
45. Zhuang S. Regulation of STAT signaling by acetylation. Cell. Signal 2013, 25:1924-1931.
46. Ray S., Lee C., Hou T., Boldogh I., Brasier A.R. Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res 2008, 36:4510-4520.
47. Gupta M., Han J.J., Stenson M., Wellik L., Witzig T.E. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 2012, 26:1356-1364.
48. Minami J., Suzuki R., Mazitschek R., Gorgun G., Ghosh B., Cirstea D., et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 2014, 28:680-689.
49. Lagneaux L., Delforge A., Bron D., De Bruyn C., Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998, 91:2387-2396.
50. Giannoni P., Scaglione S., Quarto R., Narcisi R., Parodi M., Balleari E., et al. An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease. Haematologica 2011, 96:1015-1023.
51. Wang M., Zhang W., Crisostomo P., Markel T., Meldrum K.K., Fu X.Y., et al. STAT3 mediates bone marrow mesenchymal stem cell VEGF production. J. Mol. Cell. Cardiol 2007, 42:1009-1015.
52. Lee Y.K., Shanafelt T.D., Bone N.D., Strege A.K., Jelinek D.F., Kay N.E. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005, 19:513-523.
53. Ferrajoli A., Faderl S., Van Q., Koch P., Harris D., Liu Z., et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007, 67:11291-11299.
54. Verstovsek S., Manshouri T., Quintas-Cardama A., Harris D., Cortes J., Giles F.J., et al. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin. Cancer Res 2008, 14:788-796.
55. Kong L.Y., Abou-Ghazal M.K., Wei J., Chakraborty A., Sun W., Qiao W., et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin. Cancer Res 2008, 14:5759-5768.
56. Iwamaru A., Szymanski S., Iwado E., Aoki H., Yokoyama T., Fokt I., et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007, 26:2435-2444.
57. Horiguchi A., Asano T., Kuroda K., Sato A., Asakuma J., Ito K., et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br. J. Cancer 2010, 102:1592-1599.
58. Meadows S.A., Vega F., Kashishian A., Johnson D., Diehl V., Miller L.L., et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012, 119:1897-1900.
59. Oki Y., Buglio D., Fanale M., Fayad L., Copeland A., Romaguera J., et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin. Cancer Res 2013, 19:6882-6890.
60. Su Y.C., Li S.C., Peng H.Y., Ho Y.H., Chen L.J., Liao H.F. RAD001-mediated STAT3 upregulation and megakaryocytic differentiation. Thromb. Haemost 2013, 109:540-549.